Table 5.
Tolerability and systemic adverse effects experienced by Johnson & Johnson vaccine recipients43.
| Individuals 18 to 59 |
Individuals 60 and older |
|||
| |
Mild |
Severe (resulting in debilitating symptoms) |
Mild |
Severe (resulting in debilitating symptoms) |
| Tolerability (Local and immediate reactions) | ||||
| Injection Site Pain | 58.6% | 0.4% | 33.3% | 0.2% |
| Erythema | 9.0% | 0.3% | 4.6% | 0.1% |
| Swelling | 7.0% | 0.2% | 2.7% | 0.2% |
| Systemic Reactions | ||||
| Headache | 44.4% | 0.9% | 30.4% | 0.4% |
| Fatigue | 43.8% | 1.2% | 29.7% | 0.8% |
| Myalgia | 39.1% | 1.4% | 24.0% | 0.2% |
| Nausea | 15.5% | 0.1% | 12.3% | 0.2% |
| Fever | 12.8% | 0.3% | 3.1% | 0.1% |